Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. develops fully human anti-thymocyte immunoglobulin and multi-specific human immunoglobulin G therapies for type 1 diabetes and other autoimmune diseases. Its lead program, SAB-142, is a disease-focused immunotherapy candidate for autoimmune type 1 diabetes, supported by the company’s transchromosomic cattle, or Tc-Bovine, production system for generating targeted hIgG antibodies.
Recurring news themes include SAB-142 clinical and mechanistic data, scientific conference presentations, financial results and business updates, and capital actions such as common stock and pre-funded warrant offerings that fund clinical development, manufacturing, regulatory activity and general corporate purposes.
SAB BIO (Nasdaq:SABS) reported Q1 2026 results and pipeline progress for SAB-142 in type 1 diabetes.
The Phase 2b SAFEGUARD trial continues site activation globally, with enrollment on track to complete by end-2026 and topline data expected in 2H 2027. Recent Phase 1 data showed C-peptide preservation and improved glycemic control in Stage 3 T1D.
The FDA confirmed C-peptide AUC may serve as a surrogate endpoint for accelerated approval. Cash and securities totaled $217.6 million, boosted by a $95 million public offering, providing runway through 2028. Q1 R&D was $13.4 million, G&A $6.6 million, and net loss $18.9 million. A multi-year manufacturing agreement with Emergent BioSolutions was also secured.
SAB Biotherapeutics (Nasdaq: SABS) will release first quarter 2026 financial results on the morning of Tuesday, May 12, 2026 and hold a conference call and webcast at 8:30 AM ET to discuss results and business updates.
Conference dial-in, international number, conference ID 13760144, and a replay will be available under the Investors & Media section at ir.sab.bio.
SAB BIO (Nasdaq: SABS) reported Phase 1 T1D cohort results showing C-peptide preservation in all four treated participants and a super responder profile in three of four at Day 120. Treated participants also showed CD4+ Tconv cell exhaustion and mean CGM time-in-range improvement from 73% to 85%.
The cohort included six adults (four treated, two placebo); endpoints were measured at End of Study Day 120. Data showed sustained immunomodulation without immunodepletion and no increase in exogenous insulin use.
SAB BIO (Nasdaq: SABS) will present additional clinical and mechanistic data for lead program SAB-142 at the 21st Immunology of Diabetes Society Congress, April 20-24, 2026, in Brisbane. Presentations include an oral symposium and multiple posters highlighting multi-specific binding and C-peptide findings. The SAFEGUARD study is actively enrolling with an anticipated topline readout in 2H 2027.
Presentation materials will be posted on the company website at the time of the conference.
SAB Biotherapeutics (Nasdaq: SABS) closed an underwritten public offering on March 19, 2026 of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 shares at a public offering price of $3.85 per share (pre-funded warrants at $3.8499).
Gross proceeds were approximately $85 million before fees. The company granted underwriters a 30-day option to buy up to 3,311,688 additional shares. Net proceeds will primarily fund continued development and trials of SAB-142, manufacturing, regulatory activities, and general corporate purposes.
SAB BIO (Nasdaq: SABS) priced an underwritten public offering to raise approximately $85 million in gross proceeds through the sale of 19,324,677 common shares and pre-funded warrants to purchase up to 2,753,246 shares.
The offering is expected to close on or about March 19, 2026, with a 30-day underwriter option to buy up to 3,311,688 additional shares; net proceeds will fund clinical development of SAB-142, manufacturing, regulatory and general corporate purposes.
SAB Biotherapeutics (Nasdaq: SABS) commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants on March 17, 2026. The company also plans to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities.
Proceeds, together with existing cash and marketable securities, are intended primarily to fund continued development of SAB-142 (clinical trials, manufacturing, regulatory), and for working capital and general corporate purposes. The offering is made on a Form S-3 shelf registration declared effective January 7, 2026, and is subject to market conditions.
SAB BIO (Nasdaq: SABS) reported additional Phase 1 data for SAB-142 in adults with established type 1 diabetes showing early signals of C‑peptide preservation at Day 120 in treated participants versus placebo. The small cohort (n=6; 4 treated, 2 placebo) showed biomarker evidence of T‑cell exhaustion. SAB‑142 has advanced to the registrational Phase 2b SAFEGUARD trial with topline data expected 2H 2027.
SAB BIO (Nasdaq: SABS) reported full‑year 2025 results and business highlights. Key developments include dosing multiple patients in the registrational Phase 2b SAFEGUARD study with enrollment on track to complete by end‑2026 and topline data expected in 2H 2027.
Other milestones: positive Phase 1 data supporting safety and redosability of SAB‑142, a $175 million oversubscribed private placement (with strategic investor Sanofi), and a cash position of $143.5 million providing runway through 2028.
SAB Biotherapeutics (Nasdaq: SABS) said members of management will participate in two investor conferences in Miami Beach in March 2026: the Leerink Partners Global Healthcare Conference on March 9 at 3:00 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11 at 8:30 a.m. ET.
Both appearances are in a fireside chat format. According to the company, live webcasts and archived recordings will be available in the Investors & Media section of the company website at www.sab.bio.